In many cancers, especially in most hematologic cancers, STAT5 activation and its oncogenic gene expression is not only enhanced, but also kept persistent, whereas signaling involving activation of STAT5 is rather transient under physiological conditions. This evidence concerns the gene STAT5A and hematopoietic and lymphoid cell neoplasm.